Latest Stories from Cancerdlvr.it Promoted Storieshttps://static.dlvr.it/images/d.pnghttps://static.dlvr.it/images/favicon.icotag:news.dlvr.it,2015-04-13:/category/medical/cancer2015-04-13T06:48:41-07:00tag:news.dlvr.it,2015-04-13:3669392015-04-13T06:05:42-07:00
– 30 Presentations Planned On Marketed Products and New Data from
Company’s MS Pipeline –
]]>tag:news.dlvr.it,2015-04-13:3606912015-04-13T06:01:32-07:00]]>tag:news.dlvr.it,2015-04-13:3659072015-04-13T05:38:08-07:00]]>tag:news.dlvr.it,2015-04-13:3551832015-04-13T05:05:59-07:00Exact Sciences announces expanded patient access to Cologuard as a result of several insurers now covering the test. Cologuard is now covered for more than 90 million lives across the U.S.]]>tag:news.dlvr.it,2015-04-13:3630212015-04-13T05:04:08-07:00FORMA appointed Paolo Paoletti, M.D., to its Board of Directors. He will also lead FORMA's Research & Development Committee as its chairperson. Dr. Paoletti was previously President of GSK Oncology.]]>tag:news.dlvr.it,2015-04-13:3688242015-04-13T04:10:09-07:00Cerulean today announced the publication of a manuscript in Breast Cancer Research and Treatment, describing preclinical data that demonstrate CRLX101 targets breast cancer stem cells.]]>tag:news.dlvr.it,2015-04-13:3681152015-04-13T04:01:59-07:00
Company to Accelerate Development of Cancer Product Pipeline, with
Filing of IND for Lead Product Candidate in Q2 2015
]]>tag:news.dlvr.it,2015-04-12:3555862015-04-12T22:00:09-07:00
Data to Be Presented April 22 at American Association for Cancer
Research 2015 Annual Meeting
]]>tag:news.dlvr.it,2015-04-10:3597852015-04-10T06:31:08-07:00
Underwriters fully exercise option to purchase additional shares
]]>tag:news.dlvr.it,2015-04-10:3603362015-04-10T05:02:03-07:00
Data Show Robust Silencing of CTNNB1 Gene in Patient-Derived
Xenograft and Other Cancer Models Using RNAi
]]>tag:news.dlvr.it,2015-04-10:3713682015-04-10T05:01:22-07:00New Preclinical Data on Tumor Treating Fields to be presented at the American Association for Cancer Research Annual Meeting 2015]]>tag:news.dlvr.it,2015-04-09:3726572015-04-09T14:05:21-07:00
- Conference Call and Webcast to Follow at 5:00 p.m. EDT/ 2:00 p.m.
PDT -
]]>tag:news.dlvr.it,2015-04-09:3649472015-04-09T09:16:02-07:00
Creates a broader commercial footprint and expanded product offering
in oncology diagnostics with numerous near-term product launches to
accelerate revenue growth
Enhances Rosetta Genomics’ leadership as a provider of proprietary and
differentiated content in the personalized medicine arena
Rosetta Genomics expects annualized pro forma 2015 revenues of $10
million to $12 million, and 2016 revenues to exceed $18 million
]]>tag:news.dlvr.it,2015-04-09:3688152015-04-09T09:00:15-07:00
Award* of three Phase II projects sponsored by two major American
biotech companies specializing in oncology
]]>tag:news.dlvr.it,2015-04-09:3606662015-04-09T07:02:02-07:00
Helomics’ to Present an Overview of its Personalized Comprehensive
Tumor Profiling Platform
]]>
– 30 Presentations Planned On Marketed Products and New Data from
Company’s MS Pipeline –
]]>
]]>
]]>
Exact Sciences announces expanded patient access to Cologuard as a result of several insurers now covering the test. Cologuard is now covered for more than 90 million lives across the U.S.]]>
FORMA appointed Paolo Paoletti, M.D., to its Board of Directors. He will also lead FORMA's Research & Development Committee as its chairperson. Dr. Paoletti was previously President of GSK Oncology.]]>
Cerulean today announced the publication of a manuscript in Breast Cancer Research and Treatment, describing preclinical data that demonstrate CRLX101 targets breast cancer stem cells.]]>
Company to Accelerate Development of Cancer Product Pipeline, with
Filing of IND for Lead Product Candidate in Q2 2015
]]>
Data to Be Presented April 22 at American Association for Cancer
Research 2015 Annual Meeting
]]>
Underwriters fully exercise option to purchase additional shares
]]>
Data Show Robust Silencing of CTNNB1 Gene in Patient-Derived
Xenograft and Other Cancer Models Using RNAi
]]>
New Preclinical Data on Tumor Treating Fields to be presented at the American Association for Cancer Research Annual Meeting 2015]]>
- Conference Call and Webcast to Follow at 5:00 p.m. EDT/ 2:00 p.m.
PDT -
]]>
Award* of three Phase II projects sponsored by two major American
biotech companies specializing in oncology
]]>